Abstract:Patients with metastatic breast cancer (MBC) can develop malignant effusions (MEs) when excess fluid and tumor cells accumulate in the pleural or peritoneal space. MEs are associated with significant morbidity and mortality. Tropism of tumor cells in these spaces is poorly understood and tumor cells residing in these fluids are difficult to study with traditional methods due to low abundance. To overcome this limitation and understand the pathobiology of MEs in MBCs, we applied a label-free method to isolate tumor cells based on morphology using an artificial intelligence (AI) model This method enabled isolation of live cells for downstream molecular analysis and characterization of morphological heterogeneity. We collected ME samples from 9 MBC patients with cytology-confirmed MEs, including 3 triple negative and 6 hormone receptor-positive/HER2-negative breast cancers. ME cells were imaged and isolated using a Deepcell AI model trained on a separate cohort of MEs to isolate and enrich tumor cells based on deep learning representations of morphological features. Quantitative morphological features were then extracted from cell images to perform cluster analysis and visualized by dimensionality reduction projections. In parallel, flow cytometry (FC) was used to quantify % EpCAM+/Claudin4+ tumor cells in ME samples. Copy number (CN) analysis was performed before and after enrichment with as few as 200 cells from each sample. Tumor cell fraction (TCF) estimates were calculated from the AI classifier, FC, and CN analyses. CN profiling of malignant cells sorted by the AI classifier revealed genomic alterations common in breast cancer in 7 of 9 patients. We observed increased amplitude of genomic alterations in tumor-enriched vs. unenriched samples, indicating successful tumor cell enrichment in 14 out of 16 samples. We observed a significant correlation in TCF between the AI classifier and FC with a Spearman test (rho=0.568, p0.008). In some cases, the AI classifier reported higher TCF than FC. This could indicate that the AI model detected tumor cells missed by antibody labeling or false positives from morphologically similar cell types, such as macrophages and mesothelial cells. Remarkably, analysis of serial ME samples from the same patient revealed morphological shifts in cell populations which were consistent with changes in TCF by CN analysis. We demonstrate the feasibility of label-free identification and isolation of tumor cells in MEs using an AI classifier. CN profiling of isolated tumor cells verified enrichment from low initial frequencies. Future work will include expression analysis of ME tumor and immune cells, and analysis of organoids derived from MEs. Combining molecular and morphological profiling of MEs will enable new insights into their pathobiology and inform targeted treatment strategies for patients with this condition. Citation Format: Mark J. Magbanua, Laura Huppert, Janifer Cruz, Jackson Goudreau, Shaopu Zhou, Keyi Yin, Pavel Stejskal, Ryan Carelli, Julie Kim, Linda Hsie, Maggie Wang, Zhouyang Lian, Michael Phelan, Manisha Ray, Chassidy Johnson, Amy L. Delson, Ron Balassanian, Jennifer Rosenbluth, Laura van't Veer, Michelle Melisko, Hope S. Rugo, Mahyar Salek, Maddison Masaeli, Hani Goodarzi. Artificial intelligence-assisted morphology-based detection and enrichment of malignant effusion tumor cells as a method for molecular profiling [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl) nr LB170.

Abstract 3533: Spatially Resolved Laser-Activated Cell Sorting (SLACS) and AI integration for enhanced pathological analysis and biomarker discovery

Abstract 3801: Spatially resolved laser-activated cell sorting (SLACS) for high throughput spatial cell sorting in tumor research

Abstract 6781: Spatial omics using spatially-resolved laser-activated cell sorting for cancer biomarker discovery

Abstract 471: AIM PD-L1-NSCLC: Artificial intelligence-powered PD-L1 quantification for accurate prediction of tumor proportion score in diverse, multi-stain clinical tissue samples

Abstract 4320: A novel digitally directed tissue microdissection platform integrates digital pathology with molecular analysis: Case study in metastatic colorectal cancer

Abstract 985: An innovative spatial biology biomarker discovery approach to enable acceleration of drug development

Abstract 7399: Development of a reproducible AI-based spatial biomarker of the tumor immune infiltrate on H&E slides

Abstract 1152: Pan-cancer single-cell and subcellular characterization of lymphoid aggregates and tertiary lymphoid structures using high-plex spatial molecular imaging

Abstract LB170: Artificial intelligence-assisted morphology-based detection and enrichment of malignant effusion tumor cells as a method for molecular profiling

Abstract 3771: 3D correlated multi-scale cellular and molecular architecture of solid tumors

Abstract LB245: Single cell guided identification of logic-gated cell surface combinations for selective and safe CAR therapy design

Abstract 5381: A broad-use deep learning model based on multi-dimensional morphology to identify and characterize tumor cell heterogeneity

Abstract 3803: Spatial architecture of tumor and immune cell lineages in syngeneic mouse tumor tissues

Abstract 6592: an AI Platform for Vascular and Fibrosis Analysis of Pathology Images

Abstract 2059: Machine learning integration of transcriptome-wide spatial sequencing data and ultra-high plex spatial proteomic data enables the prioritization of cancer drug targets

Abstract 4170: Artificial intelligence (AI)-based multi-modal approach using H&E and CT image for predicting treatment response of immune checkpoint inhibitor (ICI) in non-small cell lung cancer (NSCLC)

Abstract IA020: AI-powered tool for rapid & reliable bladder cancer screening and surveillance: multicenter validation efforts

Abstract 5436: Developing artificial intelligence algorithms to predict response to neoadjuvant chemotherapy in HER2-positive breast cancer

Abstract 2315: AI-enabled precision oncology era: Advanced and interactive interpretation of next-gneneration sequencing (NGS) reports

Abstract 7409: SpatialCells: Automated profiling of tumor microenvironments with spatially resolved multiplexed single-cell data

Abstract 7400: AI-driven multimodal 3D tumor modeling with spatial molecular insights for predicting ICI response in gastric cancer